

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT RESPIRATORY SYNCYTIAL VIRUS (RSV)

The purpose of this resolution is to (1) add an RSV vaccine for pregnant people aged <19 years to the VFC program, and (2) update the language regarding the recommended vaccine schedule for nirsevimab to take into account RSV vaccine for use during pregnancy.

VFC resolution —08/23-1 is repealed and replaced by the following:

A. RSV Maternal vaccine

Eligible Groups

- Pregnant people aged <19 years

Recommended Vaccination Schedule and Intervals

- During 32 through 36 weeks gestation, with seasonal administration. This would be during September through January in most of the continental United States. In jurisdictions with seasonality that differs from most of the continental United States (e.g., those with tropical climates, Alaska), providers should follow state, local, or territorial guidance on timing of administration.
- Either RSV vaccination during pregnancy at 32 through 36 weeks gestation or nirsevimab administration for infants age <8 months shortly before or during the RSV season is recommended to prevent RSV lower respiratory tract infection, but both products are not indicated for most infants.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications can be found in the package inserts available at:

<https://www.fda.gov/media/168889/download?attachment>

B. RSV Monoclonal Antibody (nirsevimab)¹

Eligible Groups

- Infants aged <8 months born during or entering their first RSV season
- Children aged 8-19 months as noted in Table 1 who are at increased risk of severe RSV disease and entering their second RSV season

Table 1. Children at increased risk of severe RSV disease

Children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season
Children with severe immunocompromise
Children with cystic fibrosis who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or weight-for-length <10th percentile
American Indian and Alaska Native children

Recommended Vaccination Schedule and Intervals

The table below summarizes the immunization schedule for administering RSV monoclonal antibody during the first and second RSV season.

Table 2. Immunization Schedule

RSV Season	Schedule	Timing
First RSV Season	One dose of nirsevimab ¹ for infants aged <8 months born during or entering their first RSV season whose mother did not receive RSV vaccine, whose mother’s receipt of RSV vaccine is unknown, or who was born within 14 days of maternal vaccination.	Administer from beginning shortly before the start of the RSV season until the end of the season
Second RSV Season	One dose of nirsevimab for children aged 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season (see Table 1)	

- For most infants aged <8 months born during or entering their first RSV season whose mother received an RSV vaccine 14 or more days prior to birth, nirsevimab¹ is not needed. Nirsevimab¹ can be considered in rare circumstances when, per the clinical judgment of the

healthcare provider, the potential incremental benefit of administration is warranted.

¹Updated administratively on 4/20/2026 to reflect licensure of an alternative RSV monoclonal antibody (clesrovimab), licensed on 6/26/2025, for use in infants during their first RSV season. Clesrovimab is not licensed for use during an infant's second RSV season. The use of brand names is not meant to preclude the use of other comparable US licensed products.

Recommended dosage

Refer to product package inserts.

Contraindications and Precautions

Contraindications and Precautions can be found in the package inserts available at:

<https://www.accessdata.fda.gov/spl/data/2f08fa60-f674-432d-801b-1f9514bd9b39/2f08fa60-f674-432d-801b-1f9514bd9b39.xml>

[If an ACIP recommendation or notice regarding RSV prevention is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: September 22, 2023

This document can be found on the CDC website at:

<https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html>